- Home
- IMUX vs SAVA Comparison
IMUX vs SAVA Comparison
Compare IMUX & SAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMUX
- SAVA
- Stock Information
- Founded
- IMUX 2016
- SAVA 1998
- Country
- IMUX United States
- SAVA United States
- Employees
- IMUX N/A
- SAVA N/A
- Industry
- IMUX Biotechnology: Pharmaceutical Preparations
- SAVA Biotechnology: Pharmaceutical Preparations
- Sector
- IMUX Health Care
- SAVA Health Care
- Exchange
- IMUX Nasdaq
- SAVA Nasdaq
- Market Cap
- IMUX 90.4M
- SAVA 102.4M
- IPO Year
- IMUX N/A
- SAVA N/A
- Fundamental
- Price
- IMUX $0.95
- SAVA $2.20
- Analyst Decision
- IMUX Strong Buy
- SAVA Hold
- Analyst Count
- IMUX 5
- SAVA 1
- Target Price
- IMUX $7.50
- SAVA $2.00
- AVG Volume (30 Days)
- IMUX 1.1M
- SAVA 739.8K
- Earning Date
- IMUX 08-07-2025
- SAVA 08-14-2025
- Dividend Yield
- IMUX N/A
- SAVA N/A
- EPS Growth
- IMUX N/A
- SAVA N/A
- EPS
- IMUX N/A
- SAVA N/A
- Revenue
- IMUX N/A
- SAVA N/A
- Revenue This Year
- IMUX N/A
- SAVA N/A
- Revenue Next Year
- IMUX N/A
- SAVA N/A
- P/E Ratio
- IMUX N/A
- SAVA N/A
- Revenue Growth
- IMUX N/A
- SAVA N/A
- 52 Week Low
- IMUX $0.56
- SAVA $1.15
- 52 Week High
- IMUX $2.11
- SAVA $33.98
- Technical
- Relative Strength Index (RSI)
- IMUX 53.93
- SAVA 48.56
- Support Level
- IMUX $0.89
- SAVA $2.11
- Resistance Level
- IMUX $1.00
- SAVA $2.43
- Average True Range (ATR)
- IMUX 0.08
- SAVA 0.14
- MACD
- IMUX -0.00
- SAVA -0.02
- Stochastic Oscillator
- IMUX 71.43
- SAVA 21.43
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
About SAVA Cassava Sciences Inc.
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease; and investigational diagnostic product candidate is called SavaDx and it is a novel way to detect the presence of Alzheimer's disease from a small sample of blood, possibly years before the overt appearance of clinical symptoms. It is currently conducting two randomized placebo-controlled Phase 3 clinical trials of oral simufilam in patients with Alzheimer's disease dementia. It has one business segment: the development of novel drugs and diagnostics.